Shrunatra Mishra's questions to Apellis Pharmaceuticals Inc (APLS) leadership • Q2 2025
Question
Shrunatra Mishra, on behalf of Salveen Richter at Goldman Sachs, asked if the guidance for low to mid-single-digit quarterly injection growth for Cyfovri is conservative and when an acceleration in this growth rate might be expected.
Answer
CEO Dr. Cedric Francois described the Cyfovri business as having achieved a stable state with steady, gradual growth. He emphasized that with only about 10% of the GA market treated, this stability provides a strong foundation to continue educating the retina community and capturing the significant long-term opportunity.